Internet Innovations in Agriculture: BioPrime Secures $6 Million for Bio-Fungicides Development

Tuesday, 8 October 2024, 21:47

Internet innovations are at the forefront as BioPrime raises $6 million in Series A funding to enhance its range of bio-fungicides. This funding will support research in crop protection, collaborating with key industry players to innovate agri-biological products. Founded by experts in 2016, BioPrime aims to improve crop yield and resilience through strategic development.
Inc42
Internet Innovations in Agriculture: BioPrime Secures $6 Million for Bio-Fungicides Development

Funding Milestone for BioPrime

Agri-focussed biotech startup BioPrime has successfully raised $6 million in its Series A funding round, led by the Belgium-based impact fund Edaphon, with participation from existing investors Omnivore and Inflexor.

Innovative Solutions for Crop Protection

This capital will enable BioPrime to fuel research in the crop protection segment, specifically focusing on developing a new range of bio-fungicides and bio-insecticides in collaboration with essential industry players.

  • Founded in 2016 by Renuka Diwan, Amit Shinde, and Shekhar Bhosale.
  • Sells a diverse range of agri-biological products.
  • Focus on promoting crop growth and resistance against biotic threats, such as insects and pests, and abiotic stresses like temperature fluctuations.

“We will continue to pursue our strategic priorities of accelerating the development of industry solutions in the biologicals space,” stated BioPrime cofounder and CEO Diwan. The goal is to enhance offerings to existing B2B customers and enter strategic co-development and licensing agreements with industry players.

Commenting on the fundraise, Edaphon managing partner Vincent Vliebergh remarked, “We invested in BioPrime because of its impressive balance between a strong portfolio of commercial products and a high-potential innovation pipeline.”


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe